Ocrevus’s Role in MS Battle May Signal Promising Trend

It produces better outcomes, is easier to administer, and costs less than competing drugs. Nothing’s perfect, but this could be the beginning of a better era for payers.

Thomas Morrow, MD

Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

PTCommunity news

New drug approvals, clinical trials, drug management. Three times per week.